Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients With Plaque-type Psoriasis

Trial Profile

A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients With Plaque-type Psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 May 2018

At a glance

  • Drugs CC 90006 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 18 May 2018 Planned End Date changed from 1 Jun 2019 to 30 Aug 2019.
    • 18 May 2018 Planned primary completion date changed from 1 Jun 2019 to 30 Aug 2019.
    • 22 Mar 2018 Planned number of patients changed from 40 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top